

Our ref: FOI 1476

27th February 2023

FOI 1476 RESPONSE

Q1. How many patients were treated in the last 3 months by the Gastroenterology department (for any medical condition) with the following biologic drugs:

- Adalimumab - Humira
- Adalimumab Biosimilar
- Filgotinib
- Golimumab
- Infliximab - Remicade
- Infliximab Biosimilar
- Ozanimod
- Tofacitinib
- Upadacitinib
- Ustekinumab
- Vedolizumab

• Adalimumab - Humira	8
• Adalimumab Biosimilar	189
• Filgotinib	0
• Golimumab	<5
• Infliximab - Remicade	0
• Infliximab Biosimilar	87
• Ozanimod	0
• Tofacitinib	6
• Upadacitinib	0
• Ustekinumab	100
• Vedolizumab	96

current patients

Part 2:

Q2. If you are able to link patient treatment to a disease, could you please provide the number of patients treated in the last 3 months for Crohn's Disease ONLY with the following biologic drugs:

- Adalimumab - Humira
- Adalimumab Biosimilar
- Golimumab
- Infliximab - Remicade
- Infliximab Biosimilar
- Upadacitinib
- Ustekinumab
- Vedolizumab

current patients

• Adalimumab - Humira	8
• Adalimumab Biosimilar	123
• Golimumab	0
• Infliximab - Remicade	0
• Infliximab Biosimilar	38
• Upadacitinib	0
• Ustekinumab	75
• Vedolizumab	39

The Trust has a legal duty to protect patient confidentiality and, in line with this duty, the figure <5 has been provided where figures are very low. This is because of the potential risk of identification of an individual. In reaching this decision the Trust has taken into account the small geographical area which the Trust serves and the sensitivity of the information requested. In addition the Trust has taken into account the fact that all information disclosed in response to an FOI is disclosed to the 'world at large' and is published on the Trust website.

S 40 (2) (third party information) of the Freedom of Information Act 2000 has been applied to exempt the redacted information from disclosure. The Trust does not consider the disclosure of the redacted information to be fair to the individuals concerned as there is the potential risk of identification of an individual(s) which they would not expect, and which would therefore breach the fairness element of the first principle of the Data Protection Act 2018.

Contact: FOI.team@southerntrust.hscni.net